Endonovo Therapeutics, Inc. (ENDV) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Endonovo Therapeutics, Inc. (ENDV) es una empresa del sector Healthcare valorada en 0. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Endonovo Therapeutics, Inc. (ENDV) Resumen de Asistencia Médica y Tuberías
Endonovo Therapeutics, Inc., operating in the biotechnology sector, develops and distributes non-invasive Electroceutical medical devices, including SofPulse, for regenerative medicine applications. The company targets palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain, positioning itself within the electroceuticals market.
Tesis de Inversión
Endonovo Therapeutics operates in the electroceuticals market, a growing segment within regenerative medicine. The company's focus on non-invasive devices offers a potential advantage over traditional treatments. The SofPulse device addresses a significant market for palliative treatment of soft tissue injuries and chronic wounds. However, the company's financial performance, as indicated by a negative P/E ratio of -0.04 and a market cap of $0.00B, raises concerns about its current profitability and valuation. The high beta of -9.79 suggests significant volatility. Future growth depends on successful clinical trials and regulatory approvals for its expanded applications, including cardiovascular and liver diseases. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty surrounding the company's long-term financial viability.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.04 reflects the company's current lack of profitability.
- Beta of -9.79 suggests an inverse correlation with the market, but also indicates high volatility.
- The company's focus on electroceuticals positions it in a growing segment of the regenerative medicine market.
- SofPulse device targets a significant market for palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain.
Competidores y Pares
Fortalezas
- Proprietary Electroceutical technology
- Non-invasive treatment approach
- Potential for expanded applications
- Focus on regenerative medicine
Debilidades
- Limited financial resources
- Lack of profitability
- Dependence on regulatory approvals
- OTC market trading
Catalizadores
- Upcoming: Clinical trial results for SofPulse in treating chronic wounds.
- Upcoming: Regulatory approvals for expanded applications of Electroceuticals in cardiovascular disease.
- Ongoing: Research and development of new Electroceutical devices for regenerative medicine.
- Ongoing: Partnerships with healthcare providers for product adoption and distribution.
- Ongoing: Expansion into international markets.
Riesgos
- Potential: Failure to obtain regulatory approvals for new applications.
- Potential: Competition from established pharmaceutical companies and medical device manufacturers.
- Potential: Negative clinical trial results for SofPulse or other Electroceutical devices.
- Ongoing: Limited financial resources and lack of profitability.
- Ongoing: Risks associated with OTC market trading, including low liquidity and potential for price manipulation.
Oportunidades de crecimiento
- Expansion of SofPulse Applications: Endonovo Therapeutics has the opportunity to expand the applications of its SofPulse device beyond its current indications. The market for chronic wound care is estimated to reach billions of dollars, and SofPulse could capture a significant share with successful clinical trials and marketing efforts. Timeline: Ongoing clinical trials with potential results within the next 12-24 months.
- Treatment of Cardio Chronic Kidney Disease: The company is exploring the use of its Electroceuticals medical device for the treatment of cardio chronic kidney disease. This represents a significant market opportunity, as chronic kidney disease affects millions of people worldwide. Successful development and commercialization of this application could drive substantial revenue growth. Timeline: Pre-clinical and early clinical trials ongoing, with potential for Phase 2 trials within 2-3 years.
- Treatment of Liver Disease NASH: Endonovo Therapeutics is also targeting liver disease non-alcoholic steatohepatitis (NASH) with its Electroceuticals technology. NASH is a growing health concern with limited treatment options, presenting a substantial market opportunity. Timeline: Pre-clinical studies underway, with potential for clinical trials in 3-5 years.
- Cardiovascular and Peripheral Artery Disease (PAD) Applications: The company is investigating the use of its Electroceuticals device for cardiovascular and peripheral artery disease (PAD). These conditions affect a large segment of the population, and a non-invasive treatment option could be highly valuable. Timeline: Early-stage research and development, with potential for pre-clinical studies in 2-3 years.
- Ischemic Stroke Treatment: Endonovo Therapeutics is exploring the application of its Electroceuticals technology for the treatment of ischemic stroke. Stroke is a leading cause of disability and death, and new treatment options are urgently needed. Timeline: Early-stage research and development, with potential for pre-clinical studies in 3-5 years.
Oportunidades
- Expansion into new therapeutic areas
- Partnerships with healthcare providers
- International market expansion
- Growing demand for non-invasive therapies
Amenazas
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Technological advancements by competitors
- Negative clinical trial results
Ventajas competitivas
- Proprietary Electroceutical technology
- Patents protecting device designs and applications
- First-mover advantage in specific electroceutical applications
- Potential for strong brand recognition with successful clinical outcomes
Acerca de ENDV
Endonovo Therapeutics, Inc., founded in 2008 and headquartered in Woodland Hills, California, is a biotechnology company specializing in the development, manufacture, and distribution of non-invasive Electroceutical medical devices. The company's core focus is regenerative medicine, with a mission to provide innovative solutions for various medical conditions through its proprietary technology. Its flagship product, SofPulse, is a non-invasive Electroceutical therapeutic device designed for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond SofPulse, Endonovo Therapeutics is exploring the application of its Electroceuticals medical device for treating a range of conditions, including cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, peripheral artery disease (PAD), and ischemic stroke. The company's business model centers on the development, manufacturing, and marketing of these devices to healthcare providers and patients. Endonovo Therapeutics operates primarily in the United States, with potential for future expansion into international markets as regulatory approvals are secured for its various applications.
Qué hacen
- Develops non-invasive Electroceutical medical devices.
- Manufactures Electroceutical devices for regenerative medicine.
- Distributes Electroceutical devices to healthcare providers and patients.
- Offers SofPulse, a therapeutic device for soft tissue injuries, chronic wounds, and post-operative pain.
- Researches and develops new applications for Electroceutical technology.
- Targets treatment of cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke.
Modelo de Negocio
- Develops and patents Electroceutical medical device technology.
- Manufactures and distributes SofPulse for palliative treatment.
- Seeks regulatory approvals for expanded applications of Electroceuticals.
- Partners with healthcare providers for product adoption and distribution.
Contexto de la Industria
Endonovo Therapeutics operates within the biotechnology industry, specifically focusing on the electroceuticals market. This market is experiencing growth driven by increasing demand for non-invasive therapies and advancements in medical device technology. The competitive landscape includes companies developing similar electroceutical devices and traditional pharmaceutical companies offering alternative treatments. Endonovo's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong market presence. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Clientes Clave
- Hospitals and clinics
- Physicians and medical professionals
- Patients with soft tissue injuries, chronic wounds, and post-operative pain
- Patients with cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke (future)
Finanzas
Gráfico e información
Precio de la acción de Endonovo Therapeutics, Inc. (ENDV): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Lows On Friday
· 28 feb 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 27 feb 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ENDV.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ENDV.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ENDV en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de ENDV
The OTC Other tier represents the lowest tier of the OTC market, indicating that Endonovo Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading in these securities carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies that are distressed, defunct, or unwilling to provide current information.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or scams
- Lack of regulatory oversight
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company has been in operation since 2008.
- Focus on developing medical devices for regenerative medicine.
- SofPulse device targets a specific market for palliative treatment.
- Company has a website and publishes press releases.
Acciones de Endonovo Therapeutics, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar ENDV?
Endonovo Therapeutics, Inc. (ENDV) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Proprietary Electroceutical technology. Riesgo principal a monitorear: Potential: Failure to obtain regulatory approvals for new applications.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ENDV?
ENDV actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ENDV?
Los precios de ENDV se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ENDV?
La cobertura de analistas para ENDV incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ENDV?
Las categorías de riesgo para ENDV incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure to obtain regulatory approvals for new applications.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ENDV?
La relación P/E para ENDV compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ENDV sobrevalorada o infravalorada?
Determinar si Endonovo Therapeutics, Inc. (ENDV) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ENDV?
Endonovo Therapeutics, Inc. (ENDV) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on OTC-traded companies.
- Financial data may not be current or audited.
- AI analysis pending for ENDV.